Cannabinoid Encyclopedia

Cannabinoid guide

What is CBDV?

A clear guide to CBDV: what it is, what researchers have studied, how strong the evidence is, and what to know about safety.

Updated July 2026 22 research sources Human and early research

The short answer

CBDV, in simple terms

CBDV is a cannabinoid-related compound represented in the scientific literature. Researchers study it for possible effects, safety, and how it works in the body. The source set includes human research as well as earlier-stage studies. The evidence does not turn this into one proven benefit, because studies can use different products, doses, routes, people, and outcomes. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBDV.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into CBDV

What CBDV is commonly talked about for

These cards show the questions most represented in this source set. They are not a list of proven benefits, and the evidence label matters as much as the topic name.

  1. Human and early-stage research

    Seizure and neurodevelopmental outcomes

    Researchers study CBDV in connection with neural signaling, behavior, or brain biology. Those findings should not be read as a proven human mood or cognition benefit. 1

    See research areas

  2. Mostly preclinical

    Endocannabinoid enzymes and metabolism

    This is part of the biological explanation for why CBDV may have effects in cells or models. Mechanism research does not by itself show a health benefit in people. 2

    See research areas

Bottom line: Start with the exact question you care about, then check the study type, product, dose, and outcome before treating a research signal as a real-world effect.

Key takeaways

What to know first

  1. 1

    Research on CBDV covers Seizure and neurodevelopmental outcomes and Endocannabinoid enzymes and metabolism; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What has CBDV been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human and early-stage research

Seizure and neurodevelopmental outcomes

Researchers have examined CBDV in connection with Seizure and neurodevelopmental outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 1

Mostly preclinical

Endocannabinoid enzymes and metabolism

Studies connect CBDV with Endocannabinoid enzymes and metabolism at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

6 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

11 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

5 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CBDV is not one kind of study. This source set includes 10 narrative or expert reviews, 4 animal studies, 4 clinical studies in people, and 1 cell or laboratory study. 3

The recorded populations or models include people or patients (11 sources), animal models (3 sources), and pediatric, adolescent, or developmental context (3 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is seizure-related or neurodevelopmental outcomes (21 sources) and endocannabinoid enzyme activity or metabolic mechanisms (1 source). Closely related outcome names can still describe different measurements. 5

The CBDV source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.

On this page, this source examines CBDV and seizure and neurodevelopmental outcomes. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
seizure-related or neurodevelopmental outcomes
Evidence stage
evidence still limited

clinical study in people

Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.

On this page, this source examines CBDV activity involving endocannabinoid enzyme activity or metabolic mechanisms. 2

Study type
clinical study in people
Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
preclinical research

systematic review or meta-analysis

Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.

On this page, this source examines CBDV and seizure and neurodevelopmental outcomes. 3

Study type
systematic review or meta-analysis
Outcome focus
seizure-related or neurodevelopmental outcomes
Evidence stage
evidence still limited

clinical study in people

Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy.

On this page, this source examines CBDV and seizure and neurodevelopmental outcomes. 4

Study type
clinical study in people
Population or model
people or patients
Outcome focus
seizure-related or neurodevelopmental outcomes
Evidence stage
human research

clinical study in people

Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.

On this page, this source examines CBDV and seizure and neurodevelopmental outcomes. 5

Study type
clinical study in people
Population or model
pediatric, adolescent, or developmental context
Outcome focus
seizure-related or neurodevelopmental outcomes
Evidence stage
preclinical research

Safety and limits

What should readers keep in mind?

Research on CBDV should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is CBDV?

CBDV is a cannabinoid-related compound studied across Seizure and neurodevelopmental outcomes and Endocannabinoid enzymes and metabolism. This page separates those research questions so they are not mistaken for one broad claim. 7

What has CBDV been studied for?

The current source set includes Seizure and neurodevelopmental outcomes and Endocannabinoid enzymes and metabolism. Each area may use different doses, products, routes, populations, and outcome measures. 8

How strong is the research on CBDV?

The source set includes human research as well as earlier-stage studies. 9

Is CBDV safe?

Safety cannot be answered for CBDV without context. Dose, route, formulation, medications, and the person using it can all change risk. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. narrative or expert review; evidence still limited PubMed 33895189 DOI 10.1016/j.pharmthera.2021.107878
  2. 2
    Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
  3. 3
    Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. systematic review or meta-analysis; evidence still limited PubMed 39541799 DOI 10.1016/j.euroneuro.2024.10.006
  4. 4
    Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. clinical study in people; human research PubMed 31748505 DOI 10.1038/s41398-019-0654-8
  5. 5
    Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. clinical study in people; preclinical research PubMed 35364618 DOI 10.1111/epi.17247
  6. 6
    Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. clinical study in people; human research PubMed 34210360 DOI 10.1186/s13229-021-00454-6
  7. 7
    Antiepileptic Drugs in Clinical Development: Differentiate or Die? narrative or expert review; evidence still limited PubMed 28799516 DOI 10.2174/1381612823666170809100524
  8. 8
    Cannabinoids for epilepsy: What do we know and where do we go? narrative or expert review; evidence still limited PubMed 29214639 DOI 10.1111/epi.13973
  9. 9
    Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. narrative or expert review; evidence still limited PubMed 32825313 DOI 10.3390/brainsci10090572
  10. 10
    Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. narrative or expert review; evidence still limited PubMed 32335286 DOI 10.1016/j.phrs.2020.104822
  11. 11
    Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. narrative or expert review; evidence still limited PubMed 42339654 DOI 10.1177/10445463261462382
  12. 12
    Investigational cannabinoids in seizure disorders, what have we learned thus far? narrative or expert review; evidence still limited PubMed 29842819 DOI 10.1080/13543784.2018.1482275
See all 22 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. narrative or expert review; evidence still limited / 1 linked research note PubMed 33895189
  2. Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. narrative or expert review; evidence still limited / 1 linked research note PubMed 32335286
  3. Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. narrative or expert review; evidence still limited / 1 linked research note PubMed 32825313
  4. Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 42339654
  5. Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? narrative or expert review; evidence still limited / 1 linked research note PubMed 33613289
  6. Investigational cannabinoids in seizure disorders, what have we learned thus far? narrative or expert review; evidence still limited / 1 linked research note PubMed 29842819
  7. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. clinical study in people; preclinical research / 1 linked research note PubMed 35364618
  8. Phytocannabinoids and epilepsy. narrative or expert review; evidence still limited / 1 linked research note PubMed 25475762
  9. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. preclinical research / 1 linked research note PubMed 24282673
  10. Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin. preclinical research / 1 linked research note PubMed 29588939
  11. Antiepileptic Drugs in Clinical Development: Differentiate or Die? narrative or expert review; evidence still limited / 1 linked research note PubMed 28799516
  12. The potential role of cannabinoids in epilepsy treatment. narrative or expert review; evidence still limited / 1 linked research note PubMed 28845714
  13. Preclinical safety and efficacy of cannabidivarin for early life seizures. animal study; preclinical research / 1 linked research note PubMed 30633929
  14. Cannabinoids for epilepsy: What do we know and where do we go? narrative or expert review; evidence still limited / 1 linked research note PubMed 29214639
  15. Cannabidivarin is anticonvulsant in mouse and rat. animal study; mechanism-focused research / 1 linked research note PubMed 22970845
  16. Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. animal study; mechanism-focused research / 1 linked research note PubMed 31447649
  17. Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. clinical study in people; human research / 1 linked research note PubMed 34210360
  18. Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36583706
  19. Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. clinical study in people; human research / 1 linked research note PubMed 31748505
  20. Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 39541799
  21. The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia. animal study; preclinical research / 1 linked research note PubMed 41159452
  22. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research / 1 linked research note PubMed 34179865